Biotechs Are On A Big Run, And Two Stocks Have Buy Points

Group 1 - Biotech stocks are prominent on the IBD 50 list, with Stoke Therapeutics (STOK) and Mirum Pharmaceuticals (MIRM) either in or forming bases [1] - A specific biotech stock has shown a sell signal after a breakout that failed to progress [1] - Biotech companies have significantly rebounded from April lows, indicating a positive trend in the sector [1] Group 2 - Novo Nordisk's stock increased due to a lighter-than-expected discount for Ozempic and Wegovy under the Inflation Reduction Act, with a price cut of 71% for Ozempic [2]